<DOC>
	<DOCNO>NCT00441168</DOCNO>
	<brief_summary>The purpose research study test safety effectiveness replace vincristine drug call bortezomib ( also know `` Velcade '' PS341 ) standard therapy vincristine , doxorubicin ( limited , formerly refer tradename Adriamycin ) dexamethasone ( VAD ) patient multiple myeloma . Multiple Myeloma second common cancer blood . Bortezomib first approve cancer treatment new class medicine call proteasome inhibitor . It disrupt cell cycle cell , affect numerous biologic pathway , include related growth survival cancer cell . The treatment use second line treatment , mean either disease return period improvement ( relapse ) disease respond initial treatment ( refractory ) . Patients receive either bortezomib ( PS341 ) , doxorubicin ( Adriamycin ) dexamethasone ( PAD ) VAD standard therapy .</brief_summary>
	<brief_title>Velcade ( Bortezomib ) , Adriamycin Dexamethasone ( PAD ) Vincristine Adriamycin Dexamethasone Second Line Treatment Multiple Myeloma</brief_title>
	<detailed_description>Bortezomib , approve use patient multiple myeloma , already receive least one prior treatment whose disease worsen last treatment already undergone unsuitable bone marrow transplantation . Bortezomib significant activity patient relapse multiple myeloma , efficacy increase addition dexamethasone demonstrate synergy doxorubicin . The VAD combination widely use multiple myeloma demonstrate effective relapsed patient . Based previous trial result , hop bortezomib , replace vincristine VAD standard therapy , improve response treatment patient multiple myeloma , manageable side effect . This international , multicentre , randomise , open-label , parallel group study . About 212 patient take part study . Patients treat either bortezomib ( PS-341 ) , Adriamycin Dexamethasone ( PAD ) Vincristine , Adriamycin Dexamethasone ( VAD ) . There initial 14 day screen period evaluate patient suitable study . After screen , eligible patient randomise receive either PAD VAD . Patients receive therapy 8 treatment cycle 28 day . After treatment period , long-term follow-up period monthly visit disease progression relapse . Thereafter follow-up continue least phone call every month . This long-term follow-up period perform patient last patient treat follow 1 year . Response treatment assess accord European group blood marrow transplant criterion ( EBMT ) . Disease burden monitor measure M-protein concentration serum urine every 4 week disease progression relapse . Thereafter follow-up survival continue every month least phone call . Safety assess monitoring adverse event ( AEs ) , vital sign , physical examination clinical laboratory test . Treatment PAD VAD 8 cycle 28 day . Treatment beyond 6 cycle discuss individual basis . Proposed dosage : bortezomib 1.3 mg/m² intravenous ( IV ) bolus Days 1 , 4 , 8 , 11 ; vincristine 0.4mg IV push Days 1 4 ; doxorubicin 9mg/m² IV push Days 1 4 ; dexamethasone 1st cycle 40 mg daily Days 1 4 , 9 12 17 20 , orally ( equivalent parenteral dose ) subsequent cycle 40 mg daily Days 1 4 17 20 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Relapsed refractory multiple myeloma follow 1 previous line therapy , schedule investigator treat vincristine , adriamycin dexamethasone standard therapy measurable secretory multiple myeloma base define criterion Karnofsky performance status &gt; = 60 % fulfils define laboratory requirement within 14 day baseline female , patient either postmenopausal surgically sterilise willing use acceptable method birth control define period time male , patient agrees use acceptable barrier method contraception define period time . More one previous line therapy multiple myeloma use bortezomib previous line therapy and/or receive bortezomib previous trial know allergy hypersensitivity bortezomib , boron mannitol peripheral neuropathy neuropathic pain grade 2 high myocardial infarction within 6 month enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>bortezomib</keyword>
	<keyword>Cancer</keyword>
	<keyword>Hematology</keyword>
	<keyword>bone marrow</keyword>
	<keyword>immunoglobulin</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>plasma cell</keyword>
	<keyword>Velcade</keyword>
	<keyword>adriamycin</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>vincristine</keyword>
</DOC>